Answers are grounded in this paper and cite their sources.
Momordica charantia L. is a popular medicinal plant used in the traditional system of medicine for the management or treatment of various diseases and disorders. This study was aimed to explore the antithrombocytopenic potential of extract and different fractions of M. charantia fruits in busulfan-induced thrombocytopenic rats. The hydroalcoholic extract (mother extract) was prepared and further fractionated based on polarity such as n-hexane, dichloromethane (DCM), n-butanol, and aqueous, respectively. Interestingly, the DCM fraction and mother extract were identified as potent antithrombocytopenic agents. DCM fractions and mother extract were metabolically characterized using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS). A total of 08 and 05 metabolites were tentatively identified in the DCM fraction and mother extract, respectively. Moreover, standardized DCM fractions and mother extract of M. charantia significantly (p<0.05) enhanced platelet count as compared to other fraction like hexane, n-butanol, and aqueous. Among all, the DCM fraction improves overall tested parameters of the blood including RBC, hemoglobin, and neutrophil. Therefore, observed results inferred that M. charantia can be used for the management of thrombocytopenia.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: